Literature DB >> 16107831

Unscrambling hepatitis C virus-host interactions.

Francis V Chisari1.   

Abstract

The human suffering exacted by the hepatitis C virus is enormous. Hundreds of thousands of people die each year from liver failure and cancer caused by this infection. There is no vaccine, and the available antiviral drugs are toxic, expensive and only partly effective. Progress has been hindered by the absence of cell culture and small-animal models of the infection. Nonetheless, recent advances have yielded several promising new antiviral drugs and enhanced the prospects of developing a vaccine. The recent development of a robust in vitro hepatitis C virus infection system will aid this search.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107831     DOI: 10.1038/nature04076

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  91 in total

1.  Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication.

Authors:  David R Blais; Rodney K Lyn; Michael A Joyce; Yanouchka Rouleau; Rineke Steenbergen; Nicola Barsby; Lin-Fu Zhu; Adrian F Pegoraro; Albert Stolow; David L Tyrrell; John Paul Pezacki
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  The phantom menace.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2006-01       Impact factor: 8.807

Review 3.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

Review 4.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 5.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

6.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

7.  Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Authors:  Robert E Lanford; Elisabeth S Hildebrandt-Eriksen; Andreas Petri; Robert Persson; Morten Lindow; Martin E Munk; Sakari Kauppinen; Henrik Ørum
Journal:  Science       Date:  2009-12-03       Impact factor: 47.728

Review 8.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.

Authors:  Zhenhua Hu; Jie Zhou; Haibo Wang; Min Zhang; Shaogang Li; Yuzhou Huang; Jian Wu; Zhiwei Li; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.

Authors:  Phillip S Pang; Paul J Planet; Jeffrey S Glenn
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.